The protease inhibitor darunavir prevents esophagitis and impairments in esophageal barrier function in a mouse model of GERD
Authors:
- Carlos Eduardo da Silva MonteiroCMCarlos Eduardo da Silva Monteiro
- Antonielle de Sousa LopesALAntonielle de Sousa Lopes
- Marco Antonio de Freitas ClementinoMCMarco Antonio de Freitas Clementino
- Antonio Carlos Pereira de OliveiraAOAntonio Carlos Pereira de Oliveira
- Lucas Antonio Duarte NicolauLNLucas Antonio Duarte Nicolau
Open Access
- 1 June 2026
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 330 (6) , G718-G726
Abstract
The gastroesophageal reflux of pepsin contributes importantly to esophageal damage in patients with GERD. We have found that darunavir, a drug presently used to treat HIV, inhibits pepsin activity and, in an animal model of GERD, darunavir reduces esophageal inflammation and HIF-2α levels while preserving levels of tight junction proteins and esophageal mucosal integrity. These findings suggest that darunavir might have a role as a novel treatment for GERD.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (309461/2020-0)
This publication has 39 references indexed in Scilit:
- Pepsin Inhibitors Prevent Inflammation and Loss of Laryngeal Barrier Function in Mice with Gastroesophageal RefluxThe Laryngoscope, 2024
- Amprenavir inhibits pepsin‐mediated laryngeal epithelial disruption and E‐cadherin cleavage in vitroLaryngoscope Investigative Otolaryngology, 2023
- Oral and Inhaled Fosamprenavir Reverses Pepsin‐Induced Damage in a Laryngopharyngeal Reflux Mouse ModelThe Laryngoscope, 2022
- Estrogen-Dependent Nrf2 Expression Protects Against Reflux-Induced EsophagitisDigestive Diseases and Sciences, 2017
- A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitisCurrent Opinion in Pharmacology, 2017
- Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic ChangesJAMA, 2016
- Management of the patient with incomplete response to PPI therapyBest Practice & Research Clinical Gastroenterology, 2013
- Pepsin promotes proliferation of laryngeal and pharyngeal epithelial cellsThe Laryngoscope, 2012
- Essential Role of Pepsin in Pathogenesis of Acid Reflux Esophagitis in RatsDigestive Diseases and Sciences, 2006
- PEPTIC ESOPHAGITISJAMA, 1935